SEARCH FINANCIAL SERVICES INFRASTRUCTURE SECURITY SCIENCE INTERVIEWS

 

     

Medtronic and Tandem Diabetes Care Ink Patent Deal

June 18, 2020

Medtronic and Tandem Diabetes Care have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each otherís patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.

With certain exclusions, this agreement applies to the companiesí existing products, as well as new products for at least the next five years, and also includes a provision not to clone one anotherís products. No payments will be exchanged as part of this agreement and further terms were not disclosed.

Terms of Use | Copyright © 2002 - 2020 CONSTITUENTWORKS SM  CORPORATION. All rights reserved. | Privacy Statement